Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation

Biochemical and Biophysical Research Communications

Volumn 390, Issue 1, 2009, Pages 48-53

  Sugimoto, Takumi ^a   Tomita, Akihiro ^a   Hiraga, Junji ^a,b   Shimada, Kazuyuki ^a   Kiyoi, Hitoshi ^c   Kinoshita, Tomohiro ^a   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOTA MEMORIAL HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD20; DNA methytransferases; Epigenetics; Histone deacetylases; Rituximab

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD20 ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; DNA METHYLTRANSFERASE 1; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; INTERFERON REGULATORY FACTOR 4; MESSENGER RNA; RITUXIMAB; TRANSCRIPTION FACTOR PU 1; TRICHOSTATIN A;

ACETYLATION; ARTICLE; B CELL LYMPHOMA; CELL TRANSFORMATION; CHROMATIN; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; AZACITIDINE; CELL LINE, TUMOR; CYTIDINE TRIPHOSPHATE; DNA METHYLATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE 1; HUMANS; LYMPHOMA, B-CELL; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS;

EID: 70349958004     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.09.059     Document Type: Article

References (30)

1. Cheson B.D. Monoclonal antibody therapy for B-cell malignancies. Semin. Oncol. 33 (2006) S2-S14
2. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., and Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 (2002) 235-242
3. Cheson B.D., and Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359 (2008) 613-626
4. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22 (2003) 7359-7368
5. Czuczman M.S., Olejniczak S., Gowda A., Kotowski A., Binder A., Kaur H., Knight J., Starostik P., Deans J., and Hernandez-Ilizaliturri F.J. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin. Cancer Res. 14 (2008) 1561-1570
6. Tomita A., Hiraga J., Kiyoi H., Ninomiya M., Sugimoto T., Ito M., Kinoshita T., and Naoe T. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int. J. Hematol. 86 (2007) 49-57
7. Hiraga J., Tomita A., Sugimoto T., Shimada K., Ito M., Nakamura S., Kiyoi H., Kinoshita T., and Naoe T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113 (2009) 4885-4893
8. Sonoki T., Li Y., Miyanishi S., Nakamine H., Hanaoka N., Matsuoka H., Mori I., and Nakakuma H. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int. J. Hematol. 89 (2009) 400-402
9. Jilani I., O'Brien S., Manshuri T., Thomas D.A., Thomazy V.A., Imam M., Naeem S., Verstovsek S., Kantarjian H., Giles F., Keating M., and Albitar M. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 102 (2003) 3514-3520
10. Kinoshita T., Nagai H., Murate T., and Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab. J. Clin. Oncol. 16 (1998) 3916
11. Davis T.A., Czerwinski D.K., and Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5 (1999) 611-615
12. Ferreri A.J., Dognini G.P., Verona C., Patriarca C., Doglioni C., and Ponzoni M. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica 92 (2007) e1-e2
13. Terui Y., Mishima Y., Sugimura N., Kojima K., Sakurai T., Kuniyoshi R., Taniyama A., Yokoyama M., Sakajiri S., Takeuchi K., Watanabe C., Takahashi S., Ito Y., and Hatake K. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin. Cancer Res. 15 (2009) 2523-2530
14. Lapalombella R., Yu B., Triantafillou G., Liu Q., Butchar J.P., Lozanski G., Ramanunni A., Smith L.L., Blum W., Andritsos L., Wang D.S., Lehman A., Chen C.S., Johnson A.J., Marcucci G., Lee R.J., Lee L.J., Tridandapani S., Muthusamy N., and Byrd J.C. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood (2008)
15. Jazirehi A.R., Vega M.I., and Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 67 (2007) 1270-1281
16. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26 (2007) 3629-3636
17. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., and Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12 (2006) 4027-4035
18. Johnson N.A., Boyle M., Bashashati A., Leach S., Brooks-Wilson A., Sehn L.H., Chhanabhai M., Brinkman R.R., Connors J.M., Weng A.P., and Gascoyne R.D. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 113 (2009) 3773-3780
19. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
20. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
21. Tomita A., Buchholz D.R., and Shi Y.B. Recruitment of N-CoR/SMRT-TBLR1 corepressor complex by unliganded thyroid hormone receptor for gene repression during frog development. Mol. Cell. Biol. 24 (2004) 3337-3346
22. Atsumi A., Tomita A., Kiyoi H., and Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem. Biophys. Res. Commun. 345 (2006) 1471-1480
23. Tomita A., Buchholz D.R., Obata K., and Shi Y.B. Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo. J. Biol. Chem. 278 (2003) 30788-30795
24. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., and Jacob S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 25 (2005) 4727-4741
25. Himmelmann A., Riva A., Wilson G.L., Lucas B.P., Thevenin C., and Kehrl J.H. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 90 (1997) 3984-3995
26. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 (2006) 1405-1428
27. Denslow S.A., and Wade P.A. The human Mi-2/NuRD complex and gene regulation. Oncogene 26 (2007) 5433-5438
28. Li J., Wang J., Nawaz Z., Liu J.M., Qin J., and Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19 (2000) 4342-4350
29. Hagenbeek A., Gadeberg O., Johnson P., Pedersen L.M., Walewski J., Hellmann A., Link B.K., Robak T., Wojtukiewicz M., Pfreundschuh M., Kneba M., Engert A., Sonneveld P., Flensburg M., Petersen J., Losic N., and Radford J. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111 (2008) 5486-5495
30. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr. Opin. Investig. Drugs 10 (2009) 588-596